Summary
- Danaher had another somewhat uneventful quarter.
- Margin in biotechnology segment improved YoY to reach 42.7% in 1Q’26.
- Life Sciences segment’s core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q’25.
- Management kept their core revenue guidance of ~3-6% but raised the high end of 2026 EPS guidance from $8.5 to $8.55.
mohd izzuan/iStock via Getty Images
Danaher (DHR) had another somewhat uneventful quarter.
Looking at Danaher’s numbers every quarter is a stark reminder of just how anemic the growth has proved to be for a company that enjoys some supposedly
754 Followers
I have background of working in the sell-side (outside the US) and in a long-only buy-side (US) shop before starting MBI Deep Dives. I also did my MBA, CFA, and FRM. I publish one Deep Dive on a publicly listed company every month.